These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 3772740)
21. Diffusion model for drug release from suspensions I: theoretical considerations. Ayres JW; Lindstrom FT J Pharm Sci; 1977 May; 66(5):654-62. PubMed ID: 874746 [TBL] [Abstract][Full Text] [Related]
22. A simplified approach for estimating skin permeation parameters from in vitro finite dose absorption studies. Lehman PA J Pharm Sci; 2014 Dec; 103(12):4048-4057. PubMed ID: 25324199 [TBL] [Abstract][Full Text] [Related]
23. Diffusion modeling of percutaneous absorption kinetics: 3. Variable diffusion and partition coefficients, consequences for stratum corneum depth profiles and desorption kinetics. Anissimov YG; Roberts MS J Pharm Sci; 2004 Feb; 93(2):470-87. PubMed ID: 14705203 [TBL] [Abstract][Full Text] [Related]
24. Distributed diffusion-clearance model for transient drug distribution within the skin. Kretsos K; Kasting GB; Nitsche JM J Pharm Sci; 2004 Nov; 93(11):2820-35. PubMed ID: 15389667 [TBL] [Abstract][Full Text] [Related]
25. Analysis of drug penetration through skin considering donor concentration decrease. Hashida M; Okamoto H; Sezaki H J Pharmacobiodyn; 1988 Sep; 11(9):636-44. PubMed ID: 3216285 [TBL] [Abstract][Full Text] [Related]
26. Numerical Investigation of Analytical Models of Drug Flux Through Microporated Skin. Pavlov AM; Rzhevskiy AS; Anissimov YG J Pharm Sci; 2019 Jan; 108(1):358-363. PubMed ID: 30439461 [TBL] [Abstract][Full Text] [Related]
27. Application of numerical methods for diffusion-based modeling of skin permeation. Frasch HF; Barbero AM Adv Drug Deliv Rev; 2013 Feb; 65(2):208-20. PubMed ID: 22261307 [TBL] [Abstract][Full Text] [Related]
28. Finite dose pharmacokinetics of skin penetration. Cooper ER; Berner B J Pharm Sci; 1985 Oct; 74(10):1100-2. PubMed ID: 4078710 [TBL] [Abstract][Full Text] [Related]
29. A compartment model for percutaneous absorption: compatibility of lag time and steady-state flux with diffusion model. Kubota K; Maibach HI J Pharm Sci; 1992 Sep; 81(9):863-5. PubMed ID: 1432629 [TBL] [Abstract][Full Text] [Related]
30. Prediction of percutaneous absorption in human using three-dimensional human cultured epidermis LabCyte EPI-MODEL. Hikima T; Kaneda N; Matsuo K; Tojo K Biol Pharm Bull; 2012; 35(3):362-8. PubMed ID: 22382322 [TBL] [Abstract][Full Text] [Related]
31. General pharmacokinetic equations for linear mammillary models with drug absorption into peripheral compartments. Vaughan DP; Mallard DJ; Trainor A; Mitchard M Eur J Clin Pharmacol; 1975 Feb; 8(2):141-8. PubMed ID: 1233210 [TBL] [Abstract][Full Text] [Related]
32. Solute-vehicle-skin interactions in percutaneous absorption: the principles and the people. Roberts MS Skin Pharmacol Physiol; 2013; 26(4-6):356-70. PubMed ID: 23921122 [TBL] [Abstract][Full Text] [Related]
33. Dynamics and control of percutaneous drug absorption in the presence of epidermal turnover. Simon L; Goyal A J Pharm Sci; 2009 Jan; 98(1):187-204. PubMed ID: 18481307 [TBL] [Abstract][Full Text] [Related]
34. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin. Nolan LM; Corish J; Corrigan OI; Fitzpatrick D Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130 [TBL] [Abstract][Full Text] [Related]
35. Significance of viable skin layers in percutaneous permeation and its implication in mathematical models: theoretical consideration based on parameters for betamethasone 17-valerate. Kubota K; Maibach HI J Pharm Sci; 1994 Sep; 83(9):1300-6. PubMed ID: 7830247 [TBL] [Abstract][Full Text] [Related]
36. First-principles, structure-based transdermal transport model to evaluate lipid partition and diffusion coefficients of hydrophobic permeants solely from stratum corneum permeation experiments. Kushner J; Deen W; Blankschtein D; Langer R J Pharm Sci; 2007 Dec; 96(12):3236-51. PubMed ID: 17887175 [TBL] [Abstract][Full Text] [Related]
37. Skin as an active metabolizing barrier I: Theoretical analysis of topical bioavailability. Ando HY; Ho NF; Higuchi WI J Pharm Sci; 1977 Nov; 66(11):1525-8. PubMed ID: 915724 [TBL] [Abstract][Full Text] [Related]
38. In Silico Simulation of Simultaneous Percutaneous Absorption and Xenobiotic Metabolism: Model Development and a Case Study on Aromatic Amines. Coleman L; Lian G; Glavin S; Sorrell I; Chen T Pharm Res; 2020 Nov; 37(12):241. PubMed ID: 33175239 [TBL] [Abstract][Full Text] [Related]
39. Vehicle effects in percutaneous absorption. Idson B Drug Metab Rev; 1983; 14(2):207-22. PubMed ID: 6341025 [No Abstract] [Full Text] [Related]
40. Finite element modeling of coupled diffusion with partitioning in transdermal drug delivery. Rim JE; Pinsky PM; van Osdol WW Ann Biomed Eng; 2005 Oct; 33(10):1422-38. PubMed ID: 16240090 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]